1.85
+0.07(+3.93%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.79 |
| Day High | 1.86 |
| Day Low | 1.75 |
| 52-Week High | 6.23 |
| 52-Week Low | 1.02 |
| Volume | 201,159 |
| Average Volume | 265,546 |
| Market Cap | 104.7M |
| PE | -1.68 |
| EPS | -1.1 |
| Moving Average 50 Days | 1.79 |
| Moving Average 200 Days | 1.89 |
| Change | 0.07 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $176.19 as of September 28, 2025 at a share price of $1.85. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $658.36 as of September 28, 2025 at a share price of $1.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage bi
TScan Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Aug 12, 2025 11:00 AM GMT
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund opera